265 related articles for article (PubMed ID: 30613299)
1. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression.
Zhao J; Zhang Z; Xue Y; Wang G; Cheng Y; Pan Y; Zhao S; Hou Y
Theranostics; 2018; 8(22):6307-6321. PubMed ID: 30613299
[TBL] [Abstract][Full Text] [Related]
2. Ferumoxytol-β-glucan Inhibits Melanoma Growth via Interacting with Dectin-1 to Polarize Macrophages into M1 Phenotype.
Liu X; Xu Y; Li Y; Pan Y; Zhao S; Hou Y
Int J Med Sci; 2021; 18(14):3125-3139. PubMed ID: 34400883
[No Abstract] [Full Text] [Related]
3. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
[No Abstract] [Full Text] [Related]
4. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth.
Cao M; Yan H; Han X; Weng L; Wei Q; Sun X; Lu W; Wei Q; Ye J; Cai X; Hu C; Yin X; Cao P
J Immunother Cancer; 2019 Nov; 7(1):326. PubMed ID: 31775862
[TBL] [Abstract][Full Text] [Related]
5. Immunologically active ferumoxytol-poly(I : C) nanomaterials inhibit metastatic melanoma by regulating myeloid-derived suppressor cell differentiation.
Fang G; Zhang Z; Jiang B; Zheng Y; Xiao X; Wang T; Zhang Z; Zhao J
Biomater Sci; 2023 Jul; 11(15):5337-5346. PubMed ID: 37366334
[TBL] [Abstract][Full Text] [Related]
6. Progranulin inhibits LPS-induced macrophage M1 polarization via NF-кB and MAPK pathways.
Liu L; Guo H; Song A; Huang J; Zhang Y; Jin S; Li S; Zhang L; Yang C; Yang P
BMC Immunol; 2020 Jun; 21(1):32. PubMed ID: 32503416
[TBL] [Abstract][Full Text] [Related]
7. IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner.
Chiba Y; Mizoguchi I; Mitobe K; Higuchi K; Nagai H; Nishigori C; Mizuguchi J; Yoshimoto T
PLoS One; 2013; 8(10):e76159. PubMed ID: 24155891
[TBL] [Abstract][Full Text] [Related]
8. ROS-Inducing Micelles Sensitize Tumor-Associated Macrophages to TLR3 Stimulation for Potent Immunotherapy.
Liu L; He H; Liang R; Yi H; Meng X; Chen Z; Pan H; Ma Y; Cai L
Biomacromolecules; 2018 Jun; 19(6):2146-2155. PubMed ID: 29669207
[TBL] [Abstract][Full Text] [Related]
9. Astrocyte indoleamine 2,3-dioxygenase is induced by the TLR3 ligand poly(I:C): mechanism of induction and role in antiviral response.
Suh HS; Zhao ML; Rivieccio M; Choi S; Connolly E; Zhao Y; Takikawa O; Brosnan CF; Lee SC
J Virol; 2007 Sep; 81(18):9838-50. PubMed ID: 17626075
[TBL] [Abstract][Full Text] [Related]
10. The combinational nano-immunotherapy of ferumoxytol and poly(I:C) inhibits melanoma via boosting anti-angiogenic immunity.
Zheng Y; Jiang B; Guo H; Zhang Z; Chen B; Zhang Z; Wu S; Zhao J
Nanomedicine; 2023 Apr; 49():102658. PubMed ID: 36708910
[TBL] [Abstract][Full Text] [Related]
11. Arginine-Based Poly(I:C)-Loaded Nanocomplexes for the Polarization of Macrophages Toward M1-Antitumoral Effectors.
Dacoba TG; Anfray C; Mainini F; Allavena P; Alonso MJ; Torres Andón F; Crecente-Campo J
Front Immunol; 2020; 11():1412. PubMed ID: 32733469
[No Abstract] [Full Text] [Related]
12. Chitosan-Poly(Acrylic Acid) Nanoparticles Loaded with R848 and MnCl
Liu X; Xu Y; Yin L; Hou Y; Zhao S
Int J Nanomedicine; 2021; 16():5675-5692. PubMed ID: 34456564
[TBL] [Abstract][Full Text] [Related]
13. Maspin inhibits macrophage phagocytosis and enhances inflammatory cytokine production via activation of NF-κB signaling.
Wang Y; Sun L; Song Z; Wang D; Bao Y; Li Y
Mol Immunol; 2017 Feb; 82():94-103. PubMed ID: 28064070
[TBL] [Abstract][Full Text] [Related]
14. Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.
Müller E; Speth M; Christopoulos PF; Lunde A; Avdagic A; Øynebråten I; Corthay A
Front Immunol; 2018; 9():2520. PubMed ID: 30450098
[TBL] [Abstract][Full Text] [Related]
15. Melanoma inhibits macrophage activation by suppressing toll-like receptor 4 signaling.
Clarke JH; Cha JY; Walsh MD; Gamboni-Robertson F; Banerjee A; Reznikov LL; Dinarello CA; Harken AH; McCarter MD
J Am Coll Surg; 2005 Sep; 201(3):418-25. PubMed ID: 16125076
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.
Shime H; Matsumoto M; Oshiumi H; Tanaka S; Nakane A; Iwakura Y; Tahara H; Inoue N; Seya T
Proc Natl Acad Sci U S A; 2012 Feb; 109(6):2066-71. PubMed ID: 22308357
[TBL] [Abstract][Full Text] [Related]
17. Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages.
Sommariva M; Le Noci V; Storti C; Bianchi F; Tagliabue E; Balsari A; Sfondrini L
Cell Immunol; 2017 Mar; 313():52-58. PubMed ID: 28089340
[TBL] [Abstract][Full Text] [Related]
18. BRCA-1 depletion impairs pro-inflammatory polarization and activation of RAW 264.7 macrophages in a NF-κB-dependent mechanism.
Morrone MDS; Somensi N; Franz L; Ramos VM; Gasparotto J; da Rosa HT; Sartori M; Figueiró F; Gelain DP; Zanotto-Filho A; Moreira JCF
Mol Cell Biochem; 2019 Dec; 462(1-2):11-23. PubMed ID: 31446616
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity.
Whitmore MM; DeVeer MJ; Edling A; Oates RK; Simons B; Lindner D; Williams BR
Cancer Res; 2004 Aug; 64(16):5850-60. PubMed ID: 15313929
[TBL] [Abstract][Full Text] [Related]
20. The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects.
Ding L; Ren J; Zhang D; Li Y; Huang X; Ji J; Hu Q; Wang H; Ni Y; Hou Y
Mol Cancer Ther; 2017 Jun; 16(6):1068-1079. PubMed ID: 28138030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
